License to kill: IFN-λ regulates antifungal activity of neutrophils.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Targeting the Granulocytic Defense againstInternational journal of molecular sciences · 2023
   Article
2. Selective Janus kinase inhibition preserves interferon-λ-mediated antiviral responses.Science immunology · 2021
   Article
3. Insights Into Type I and III Interferons in Asthma and Exacerbations.Frontiers in immunology · 2020
   Review
4. Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2019
   Article
5. Interferon-λ orchestrates innate and adaptive mucosal immune responses.Nature reviews. Immunology · 2019
   Review

Corrections and comments

• Comment on
  Type III interferon is a critical regulator of innate antifungal immunity.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as